Clinical Trials Directory

Trials / Terminated

TerminatedNCT04398368

Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study

GEMINI: An Open-Label, Single-Arm, Phase II Study of Intraoperative Gemcitabine Intravesical Instillation in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
25 (actual)
Sponsor
Mayo Clinic · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase II trial studies how well gemcitabine works in preventing urothelial cancer from coming back within the bladder (intravesical recurrence) in patients with upper urinary tract urothelial cancer undergoing radical nephroureterectomy. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Instilling gemcitabine into the bladder during surgery, may reduce the chance of recurrence of upper urinary tract urothelial cancer.

Detailed description

PRIMARY OBJECTIVE: I. To determine the efficacy of a single intraoperative intravesical instillation of gemcitabine hydrochloride (gemcitabine) at time of radical nephroureterectomy (RNU) for clinically localized upper tract urothelial carcinoma (UTUC) in preventing intravesical recurrence of urothelial cancer (UC) at one year. SECONDARY OBJECTIVES: I. To assess time to recurrence for entire duration of follow-up. II. To assess the qualitative and quantitative toxicities. EXPLORATORY OBJECTIVES: I. To stratify intravesical UC recurrence free survival by tumor grade, neoadjuvant chemotherapy, tumor stage, ureteral tumor location, and history of bladder cancer. II. To assess incidence and time to development of muscle-invasive bladder cancer (MIBC). OUTLINE: Patients receive gemcitabine hydrochloride intravesically for at least 1 hour at the time of RNU. After completion of study, patients are followed up at 2 weeks, and 3, 6, 12, 18, and 24 months.

Conditions

Interventions

TypeNameDescription
DRUGGemcitabine HydrochlorideGiven intravesically

Timeline

Start date
2020-06-05
Primary completion
2023-02-02
Completion
2023-02-02
First posted
2020-05-21
Last updated
2023-08-08
Results posted
2023-08-08

Locations

4 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04398368. Inclusion in this directory is not an endorsement.